The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
115005037 11500503 7 F 2006 20160825 20150914 20160902 EXP US-PFIZER INC-2015294399 PFIZER 83.00 YR F Y 68.00000 KG 20160902 CN US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
115005037 11500503 1 PS LYRICA PREGABALIN 1 Oral 125 MG, 3X/DAY 21446 125 MG CAPSULE, HARD TID
115005037 11500503 2 SS LYRICA PREGABALIN 1 Oral 100 MG, 1X/DAY 21446 100 MG CAPSULE, HARD QD
115005037 11500503 3 SS LYRICA PREGABALIN 1 Oral 75 MG, 2X/DAY 21446 75 MG CAPSULE, HARD BID
115005037 11500503 4 SS LYRICA PREGABALIN 1 Oral UNK, 2X/DAY 21446 CAPSULE, HARD BID
115005037 11500503 5 SS LYRICA PREGABALIN 1 Oral 50 MG, UNK 21446 50 MG CAPSULE, HARD
115005037 11500503 6 SS LYRICA PREGABALIN 1 Oral 100 MG, 3X/DAY L85797 21446 100 MG CAPSULE, HARD TID
115005037 11500503 7 C ELIQUIS APIXABAN 1 2.5 MG, 2X/DAY 0 2.5 MG BID
115005037 11500503 8 C DILTIAZEM. DILTIAZEM 1 100 MG, 1X/DAY 0 100 MG CAPSULE QD
115005037 11500503 9 C DILTIAZEM. DILTIAZEM 1 180 MG, 1X/DAY 0 180 MG CAPSULE QD
115005037 11500503 10 C FLECAINIDE FLECAINIDE 1 50 MG, 2X/DAY 0 50 MG BID
115005037 11500503 11 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 1 DF (42/2.0MG), 1X/DAY 0 1 DF QD
115005037 11500503 12 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 40 MG, UNK 0 40 MG
115005037 11500503 13 C ATORVASTATIN ATORVASTATIN 1 20 MG, 1X/DAY 0 20 MG QD
115005037 11500503 14 C CENTRUM SILVER MINERALSVITAMINS 1 UNK 0
115005037 11500503 15 C CALCIUM WITH VITAMIN D CALCIUMVITAMIN D 1 100 MG, UNK 0 100 MG
115005037 11500503 16 C MIRALAX POLYETHYLENE GLYCOL 3350 1 UNK 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
115005037 11500503 1 Hypoaesthesia
115005037 11500503 2 Back pain
115005037 11500503 3 Pain in extremity
115005037 11500503 11 Gastrooesophageal reflux disease
115005037 11500503 16 Constipation

Outcome of event

Event ID CASEID OUTC COD
115005037 11500503 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
115005037 11500503 Dizziness
115005037 11500503 Drug ineffective
115005037 11500503 Fall
115005037 11500503 Impaired driving ability
115005037 11500503 Limb discomfort
115005037 11500503 Nausea

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
115005037 11500503 1 2001 0
115005037 11500503 6 201510 0
115005037 11500503 7 2006 0
115005037 11500503 8 2006 0
115005037 11500503 10 2010 0
115005037 11500503 11 2000 0
115005037 11500503 12 2010 0
115005037 11500503 14 1990 0
115005037 11500503 15 1990 0
115005037 11500503 16 2010 0